Related Experiment Video
Updated: May 23, 2026

Venous Thrombosis Assay in a Mouse Model of Cancer
Published on: January 5, 2024
Treating venous thromboembolism in patients with cancer
Caroline Piatek1, Casey L O'Connell, Howard A Liebman
1Jane Anne Nohl Division of Hematology, Department Medicine, University of Southern California-Keck School of Medicine, Los Angeles, CA 90033, USA.
Abstract:
Venous thromboembolism (VTE) is a major cause of morbidity and mortality among patients with cancer. Although much is known about the factors that contribute to VTE risk, pre-emptive therapy in high-risk populations is clearly indicated in only a few clinical situations. Low-molecular-weight heparin is still the recommended class of anticoagulants for cancer-associated VTE. Management of VTE in patients with renal failure, hemorrhagic brain metastases, thrombocytopenia and coagulopathy remains challenging with few safe and effective alternatives. Novel oral agents are currently being investigated and may play a role in the future in the treatment of cancer-associated VTE.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Pulmonary Embolism III: Nursing Management
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis I: Introduction
